Hypertension in Pregnancy Clinical Trial
Official title:
Docosahexaenoic Acid Supplementation of Women With Hypertension in Pregnancy to Improve Endothelial Health and Reduce the Risks of Preterm Delivery
The Investigator would like to see if taking a DHA supplement at a dose recommended for heart health will improve brachial artery dilation (relaxation) and help blood pressure. As a second goal the Investigator would like to see if this supplement can delay preterm delivery by improving heart health. In this research study, the Investigator is asking pregnant women with chronic high blood pressure to take Expecta (DHA - Martek Biosciences, now known as DSM Nutritional Lipil) during the last half of their pregnancy until six weeks after they deliver their baby.
The Investigator will be supplementing pregnant mothers with Expecta. This is an over the counter supplement often used by pregnant and nursing mothers and will be given to expectant mothers during the research study. This DHA supplement is available to anyone at most any store. The dose often used over the counter is 200mg, we are testing the heart recommended dose of 1000mg. Because the Investigator is using the heart health recommended dose and because there may be a health claim, the Investigator is doing the study using an FDA- food and drug administration IND. IND means investigational drug. This dose has recently been used safely and effectively in pregnancy both here in the United States and in Australia in hundreds of women. There are no risks to the fetus as the placenta prefers to transfer this important nutrient for fetal eye and brain development. The large studies done in pregnancy have followed their babies into school age and found no adverse effects. ;
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00974714 -
L-arginine Effects on Chronic Hypertension in Pregnancy
|
Phase 3 | |
Terminated |
NCT03595982 -
Is Procardia XL 60 mg Q Daily Equivalent to 30 mg XL Given Twice Daily?
|
Phase 4 | |
Completed |
NCT04486170 -
Assessment of Postpartum Education to Improve Compliance
|
N/A | |
Completed |
NCT03506724 -
Response to Anti-hypertensives in Pregnant and Postpartum Patients
|
Phase 4 | |
Completed |
NCT03613714 -
Innovation in Postpartum Care for Women With Hypertensive Disorders of Pregnancy
|
N/A | |
Recruiting |
NCT04604535 -
The BEET-BP Trial - Investigating the Effect of Dietary Nitrates on Hypertension in Pregnancy
|
N/A | |
Completed |
NCT00412230 -
Insulin Resistance and Hypertensive Disorders in Pregnancy
|
N/A | |
Active, not recruiting |
NCT05049616 -
Oral Combined Hydrochlorothiazide/Lisinopril Versus Oral Nifedipine for Postpartum Hypertension
|
Phase 4 | |
Completed |
NCT04119232 -
Randomized Clinical Trial to Increase Physical Activity After a a Hypertensive Pregnancy
|
N/A | |
Completed |
NCT04633551 -
Vascular Inflammation and Anti-inflammatory Supplements After Adverse Pregnancy Outcomes
|
N/A | |
Completed |
NCT05859282 -
Development and Validation of a Short Tool to Assess the Awareness of Pregnancy-induced Hypertension
|
||
Active, not recruiting |
NCT05543265 -
Bridging the Gap From Postpartum to Primary Care
|
N/A | |
Completed |
NCT00571766 -
Effects of Oral L-Arginine on Chronic Hypertension in Pregnancy
|
Phase 3 | |
Recruiting |
NCT05473767 -
Expanding the Family Check-Up in Early Childhood to Promote Cardiovascular Health of Mothers and Young Children
|
N/A | |
Recruiting |
NCT05683093 -
Cardiovascular Longitudinal ALSPAC Research Investigations Following Hypertensive Pregnancy in Young Adulthood
|
||
Completed |
NCT06403722 -
Perinatal Outcomes in Patients With Elevated sFlt-1/PlGF Ratio
|
||
Recruiting |
NCT05852054 -
Supporting Transitions to Primary Care Among Under-resourced, Postpartum Women (STEP-UP)
|
Phase 3 | |
Recruiting |
NCT05137808 -
Understanding Blood Pressure Changes After Birth
|
||
Completed |
NCT03961360 -
Effectiveness of Higher Aspirin Dosing for Prevention of Preeclampsia in High Risk Obese Gravida
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT03648645 -
Hypertensive Pregnant Women Monitored by Teletransmitted Self-measurements of Blood Pressure
|
N/A |